Passionately committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant (MDR), gram-negative infections
We are a late-stage biopharmaceutical company committed to treating serious infections.
Learn more about Our Pipeline.
Achaogen Appoints Halley Gilbert to Its Board of Directors
January 5, 2017
Achaogen Announces Pricing of Public Offering of Common Stock
December 14, 2016
Achaogen Announces Proposed Public Offering of Common Stock
December 12, 2016
See more press releases and publications.